{"schema_version":"secwatch.filing_event.v1","accession":"0001447362-22-000135","form_type":"8-K","ticker":"CSTL","cik":"0001447362","company_name":"CASTLE BIOSCIENCES INC","filed_at":"2022-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.801279+00:00","generated_at":"2026-06-24T02:43:22.524079+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Castle Q2 revenue $34.8M (+53%); raises 2022 guidance to $130-135M","bullets":["Q2 total test reports 11,034 (+57% YoY); skin cancer GEP volume up 44% YoY.","Net loss $(1.6)M improved from $(8.8)M; adjusted EBITDA $(10.9)M vs $(3.4)M.","2022 revenue guidance raised to $130-135M from $118-123M; cash $273M.","DecisionDx-Melanoma test linked to 27% improvement in melanoma-specific survival in NCI collaboration."],"urls":{"canonical":"https://secwatch.observer/filing/0001447362-22-000135","json":"https://secwatch.observer/filing/0001447362-22-000135.json","markdown":"https://secwatch.observer/filing/0001447362-22-000135.md","text":"https://secwatch.observer/filing/0001447362-22-000135.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447362/000144736222000135/0001447362-22-000135-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447362/000144736222000135/cstl-20220808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:43:22.524079+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}